WHO ICTRP trial
Study to improve uremic pruritus
JPRN-jRCT1041240033 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT1041240033 |
|---|---|
| Public title | Study to improve uremic pruritus |
| Scientific title | Comparison of the effects of intravenous difelikefalin acetate and oral nalfurafine hydrochloride on improving uremic pruritus (multicenter joint study) |
| Primary sponsor | Fujimoto Keiji |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | none;Japan |
| Conditions | Uremic pruritus |
| Interventions | Control drug group: Nalfurafine hydrochloride 2.5 mcg/day before bedtime Study drug group: Difelikefalin acetate 0.5 mcg/kg/dose, intravenous injection, 3 doses per week at the end of dialysis |
| Registration date | May 24, 2024 |
| Target size | 60 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: